• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
RAC

RACE ONCOLOGY LTD - News & Media

9.29% ! $1.53
Market Cap $265.8M  !
Healthcare Biotechnology
Add to My Watchlist

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a... Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.More

Corporate Spotlight

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.
View the full Corporate Spotlight arrow Created with Sketch.

RAC Accelerates Game-Changing Cancer Drug

Articles & Videos

Race Oncology accelerates gamechanging cancer drug

In this HotCopper Capital Compass interview, Race Oncology (ASX:RAC) chairman Dr Pete Smith discusses the company’s @safe and successful” Phase One clinical trials and the RC220 plus doxorubicin dosing done at the time.Listen to the HotCopper podcast for in-d...

02 Jul 2025 09:48 (AEST)

Race Oncology approved for Phase I trial for chemotherapeutic treatments

Race Oncology Ltd has received approval to go ahead with its Phase I trial to assess R220 and begin enrolling patients

14 Mar 2025 10:10 (AEDT)

Race identifies 39 new molecules with potential to inhibit cancer-associated protein

Race Oncology Ltd has completed a successful drug discovery program started in 2022 at Monash University in Melbourne

21 Nov 2024 11:39 (AEDT)

Race delivers promising results in cancer drug mice research into heart complications

Race Oncology (ASX:RAC) has announced a preclinical breakthrough in heart toxicity side effects caused by the carfilzomib, which had precluded the drug being administered to patients diagnosed with elevated cardiac risk factors.In work performed under contract by Labcorp in the United States, Rac...

13 Jun 2024 11:12 (AEST)

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug bisantrene

14 May 2024 09:56 (AEST)

Race Oncology flags bisantrene "anticancer" properties in animals

Race Oncology (ASX:RAC) presented some major advancements in the potential treatment of Acute Myeloid Leukemia (AML)

06 Mar 2024 11:25 (AEDT)

Dr Daniel Tillett takes the helm as CEO of Race Oncology

Race Oncology (ASX:RAC) has appointed Dr Daniel Tillett as its newest Chief Executive Officer, effective immediately.

22 Nov 2023 10:24 (AEDT)

Race Oncology confirms RC220 peripheral infusion safety in preclinical models

Race Oncology (ASX:RAC) has completed its series of preclinical animal and laboratory studies using its novel bisantrene formulation, RC220.

17 Oct 2023 11:02 (AEDT)

Race Oncology manufactures first cGMP bisantrene batch with Laurus Labs

Race Oncology (ASX:RAC) produces its first batch of bisantrene dihydrochloride under cGMP standards through its partnership with Laurus Labs.

27 Sep 2023 10:57 (AEST)

Race Oncology's (ASX:RAC) bisantrene demonstrates broad anti-cancer activity in latest test results

Race Oncology (ASX:RAC) has announced successful test results of its Bisantrene anti-cancer medication showing broad "anti-cancer activity" in 143 human cancer cell samples.

21 Sep 2023 14:45 (AEST)



Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
$1.53 		Change
0.130(9.29%) 		Mkt cap ! $265.8M
Open High Low Value Volume
$1.42 $1.58 $1.42 $655.1K 433.0K

Buyers (Bids)

No. Vol. Price($)
1 12737 $1.53
 

Sellers (Offers)

Price($) Vol. No.
$1.54 10000 1
View Market Depth
Last trade - 16.13pm 05/09/2025 (20 minute delay) ?
Last
$1.52 		  Change
0.130 ( 9.52 %)
Open High Low Volume
$1.44 $1.58 $1.44 28912
Last updated 15.58pm 05/09/2025 ?
RAC (ASX) Chart

Top Stories

Lotus Res sinks -16% to match 19cps raising price; shareholder reaction mixed

Lotus Resources (ASX:LOT) has fallen -16% in Thursday trades after raising A$65M in a placement to recommence uranium mining activites in Mali and works on a separate project in Botswana. As ever, raising has prompted mixed reactions on the HotCopper forums, separating the true believers from the...
Listen: HotCopper Wire Podcast 023 – Glowing gold, shining silver, and... wheat collusion? In this HotCopper Wire episode, we look at surging gold and silver as well as Trump's appeals court clash, and a wheat futures conspiracy.
Plug Power has turned around, Pure Hydrogen, nucera, and Nel ASA with top news Hydrogen stocks remain volatile: thyssenkrupp nucera struggles, Pure Hydrogen expands, Plug Power shows growth, while Nel ASA faces setbacks.
Haranga Resources on the cusp of drilling at Lincoln Gold once dewatering concludes Haranga Resources (ASX:HAR) has offered investors a glimpse into the on-site machinations of its Lincoln Gold Project on Thursday, citing an imminent plan. to kick off drilling at the project (while the yellow metal enjoys fresh record highs) as soon as de-watering of existing assets is complete....
Lithium Universe, now looking at silver extraction from solar panels, boasts 95% recovery Lithium Universe (ASX:LU7) has reported hitting silver recovery metrics of over 95% from discarded solar panels in a tech validation trial alongside Macquarie Uni focusing on Jet Electrochemical Silver Extraction (JESE) @ with the lion’s share recovered in as little as 7 minutes o...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.